Viatris/$VTRS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Viatris

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Ticker

$VTRS
Sector
Primary listing

Employees

32,000

Viatris Metrics

BasicAdvanced
$12B
-
-$2.92
0.90
$0.48
4.69%

What the Analysts think about Viatris

Analyst ratings (Buy, Hold, Sell) for Viatris stock.

Bulls say / Bears say

Viatris’ Q2 2025 revenue of $3.58 billion and adjusted EPS of $0.62 both surpassed consensus forecasts ($3.47 billion and $0.56 respectively), showing strong operational execution despite generic competition. (Reuters)
On a divestiture-adjusted operational basis, Q2 net sales rose 3%, driven by strong brand performance in Greater China and Emerging Markets, demonstrating Viatris’ diversified revenue streams. (Reuters)
Year-to-date through Q2, Viatris returned over $630 million to shareholders, including $350 million in stock buybacks, and reiterated $500 million–$650 million buyback guidance for 2025, highlighting robust free cash flow. (Reuters)
Viatris fell 11.3% in premarket trading after issuing 2025 revenue guidance of $13.5 billion–$14 billion, below the $14.27 billion analysts expected, and adjusted EPS guidance of $2.12–$2.26 versus a $2.59 consensus, highlighting growth challenges. (Reuters)
The company’s Q4 adjusted profit per share of $0.54 and sales of $3.52 billion missed estimates of $0.57 per share and $3.61 billion, pointing to operational headwinds. (Reuters)
The company estimates the FDA warning letter at its Indore facility will lower 2025 revenues by around $500 million and adjusted EBITDA by approximately $385 million, underscoring ongoing regulatory and supply chain risks. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

Viatris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Viatris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VTRS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Sept15
Viatris
DividendPayment
$0.12Per share
FAQs